Center-Authored Papers

Filters: Author is Harrington, Kimberly H  [Clear All Filters]
2016
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2016.  Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 9(1):133.
Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, Meshinchi S, Walter RB.  2016.  Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.. Oncotarget. 7(28):43281-43294. Abstract
2015
Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB.  2015.  The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.. PloS one. 10(8):e0135945. Abstract
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2015.  High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 8(1):115. Abstract
2014
Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S et al..  2014.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 55(12):2817-21. Abstract
2013
Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB.  2013.  High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 54(1):202-204.
Laszlo GS, Gudgeon CJ, Harrington KH, Dell'aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB.  2013.  Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.. Blood. Abstract
Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE et al..  2013.  AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.. PloS one. 8(1):e53518. Abstract
Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP et al..  2013.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.. Blood. 122(8):1455-63. Abstract
Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC et al..  2013.  Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group.. American journal of hematology. 88(8):694-702. Abstract